ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
438 articles with ImmunoGen Inc.
-
Here's a roundup of some of the top clinical trial news from the previous week.
-
ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer
5/15/2019
ImmunoGen, Inc. announced mature data from the FORWARD II expansion cohort evaluating mirvetuximab soravtansine in combination with Avastin® in patients with folate receptor alpha-positive platinum-resistant ovarian cancer.
-
Good, but Not Good Enough: FDA Urges ImmunoGen to Run Another Phase III Trial for Ovarian Cancer ...
5/15/2019
The FDA told the company that the results from the trial didn’t meet its primary endpoint under the pre-specified statistical analysis plan and the data around the secondary endpoints couldn’t be used to support an accelerated approval application. -
ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results
5/3/2019
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2019.
-
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results
4/18/2019
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 3, 2019
-
ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer
3/1/2019
ImmunoGen, Inc. announced that its Phase 3 FORWARD I trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in either the entire study population or in the pre-specified subset of patients with high FRα expression.
-
ImmunoGen’s FORWARD I trial was testing the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer.
-
ImmunoGen Announces Multiple Presentations at AACR Annual Meeting
2/27/2019
First-in-Class ADAM9-targeting ADC, IMGC936, Developed in Collaboration with MacroGenics, Demonstrates Preclinical Activity in Models of Non-Small Cell Lung, Gastric, and Colorectal Cancers
-
ImmunoGen Reports Recent Progress and 2018 Operating Results
2/8/2019
Top-Line Data from Phase 3 FORWARD I Mirvetuximab Soravtansine Study on Track for First Half of 2019
-
ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results
1/24/2019
ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 8, 2019 to discuss its 2018 operating results.
-
ImmunoGen Announces Sale of Residual Kadcyla Royalties
1/8/2019
ImmunoGen, Inc. today announced the sale of its residual rights to receive royalty payments on commercial sales of Kadcyla® (ado-trastuzumab emtansine) to OMERS
-
ImmunoGen Announces Webcast of Presentation and Q&A at the 37th Annual J.P. Morgan Healthcare Conference
1/2/2019
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 37th Annual J.P. Morgan Healthcare Conference in San Francisco.
-
ImmunoGen Presents New Data Highlighting Potential of Novel ADCs in Oral Presentations at ASH Annual Meeting
12/1/2018
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new data from the ongoing Phase 1 studies of IMGN632 and IMGN779, next-generation CD123- and CD33-targeting ADCs
-
ImmunoGen Announces Resignation of Chief Financial Officer
11/26/2018
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that David B. Johnston has stepped down as Chief Financial Officer of the Company, with immediate effect
-
Over 76 Data Driven Presentations on Cancer Treatment Research to be Presented at the 9th Annual World Antibody-Drug Conjugate Conference in San Diego, November 12-15
11/8/2018
The Antibody-Drug Conjugate community will join together for the 9th World ADC San Diego on November 12-15 at the Marriott Marquis San Diego with key influential researchers from around the world, to discuss clinical research experiences to help further the development of cancer therapeutics.
-
ImmunoGen Announces Webcasts of Presentations at Upcoming November 2018 Conferences
11/6/2018
ImmunoGen, Inc. today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
-
ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results
11/2/2018
Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine with KEYTRUDA® Reported at ESMO
-
ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 60th ASH Annual Meeting
11/1/2018
ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that abstracts highlighting two of the Company’s experimental ADC therapies, IMGN779 and IMGN632, have been accepted for presentations at the upcoming American Society of Hematology (ASH) Annual Meeting to be held December 1-4 in San Diego, California.
-
ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 Congress
10/20/2018
ImmunoGen Inc, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab soravtansine
-
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2018 Operating Results
10/18/2018
ImmunoGen, Inc. today announced that Company will host a conference call at 8:00a.m. on Friday, Nov 2, 2018.